This chapter discusses advances in ovarian cancer
chemotherapy. Ovarian cancer is one of the deadliest diseases that affect women
worldwide. Unfortunately, most women with ovarian cancer receive a diagnosis
when the disease has progressed to stages 3 or 4, which makes recovery from the
disease difficult. The likelihood of survival
is increased in women with early-stage disease who are able to commence
treatment early as a consequence of early detection. While the majority of the
patients respond well to first-line treatment, i.e. cytoreductive surgery
integrated with platinum-based chemotherapy, the rate of disease recurrence is
very high and the available treatment options for recurrent disease are not
curative. Thus, more potent ovarian cancer therapy options are therefore
required. In the fight against ovarian cancer, targeted drug conjugate systems
have become a potentially effective therapeutic approach. With the help of
these systems, it is possible to administer chemotherapeutic agents to ovarian
cancer while protecting healthy cells.
To promote the clinical translation of these drug conjugate systems, it
is important to develop and utilize improved pre-clinical tumor models that
more accurately mimic ovarian tumors in humans during the preclinical phase of
drug development. Additionally, targeted drug conjugate systems improve
therapeutic efficacy by facilitating drug accumulation in the tumor and
minimizing the incidence of adverse effects. In this chapter, different
targeted drug conjugate systems that have been developed or are being developed
for the treatment of ovarian cancer are discussed.
Author(s) Details:
Omotola D. Ogundipe
Department of Pharmaceutical Sciences, Howard University,
Washington, DC, USA.
Oluwabukunmi
Olajubutu
Department of Pharmaceutical Sciences, Howard University, Washington, DC,
USA.
Simeon K. Adesina
Department of Pharmaceutical Sciences, Howard University, Washington, DC,
USA.
Please see the book here:
https://doi.org/10.9734/bpi/prrat/v1/8457E
No comments:
Post a Comment